What is claimed is:

1. An implantable drug delivery system comprising:

a housing suitable for implantation in a patient;
storage means for storing a quantity of drug in a dry powder form,
metering means for metering a predetermined, effective amount of the drug; and
delivery means for delivering an effective amount of the drug to a patient to treat
a disorder.

2. An implantable drug delivery system according to claim 1 wherein the delivery means comprises:

a catheter having a plurality of drug delivery ports, the drug delivery ports being movable between an open position to deliver the drug to the patient, and a closed position; and

drug delivery path preservation means for resisting fibrous occlusion of the drug delivery ports.

3. An implantable drug delivery system comprising:

a housing suitable for implantation in a patient,
a storage chamber for storing a quantity of drug,
metering means for metering a predetermined, effective amount of the drug; and
delivery means for delivering an effective amount of the drug to a patient to treat
a disorder.

4. An implantable drug delivery system according to claim 3 wherein the storage means comprises a plurality of storage compartments,

the metering means comprises a plurality of micro-channels capable of communicating with the storage compartments, a mixing chamber, and valve means capable of being opened to afford fluid communication with the storage compartments.

Patent Application Attorney Docket: AMS-161

- 5. An implantable drug delivery system according to claim 4 further comprising indexing means for affording indexed communication between the mixing chamber and a micro-channel.
- 6. An implantable drug delivery system according to claim 3 wherein the drug comprises prostaglandin E1.
- 7. An implantable drug delivery system according to claim 3 wherein the system includes a catheter with drug delivery ports that are sized and shaped to be implanted in a corporal body region of the patient.
- 8. An implantable drug delivery system according to claim 7 wherein the catheter includes a coating of poly(glycine-valine-glycine-valine-proline).
- 9. An implantable drug delivery system according to claim 3 wherein the device includes a drug delivery port, and

storage means for a substance for resisting fibrous occlusion of the drug delivery port.

- 10. An implantable drug delivery system according to claim 9 wherein the substance for resisting fibrous occlusion comprises a biodegradable polymer.
- 11. An implantable drug delivery system according to claim 3 wherein the delivery means comprises a pump.
- 12. An implantable drug delivery system according to claim 4 wherein the valve means are battery powered.
- 13. An implantable drug delivery system comprising: storage means for storing a drug,

metering means for metering a predetermined, effective amount of the drug; delivery means for delivering an effective amount of the drug to a patient to treat a disorder, the delivery means comprising:

a catheter having a plurality of drug delivery ports, the drug delivery ports being movable between an open position to deliver the drug to the patient, and a closed position; and

drug delivery path preservation means for resisting fibrous occlusion of the drug delivery ports.

- 14. An implantable drug delivery system according to claim 13, wherein the drug delivery path preservation means comprises poly(glycine-valine-glycine-valine-proline) associated with the catheter.
- 15. A drug delivery system according to claim 13, wherein the catheter has a longitudinal axis and the drug delivery ports comprise a plurality of slits.
- 16. An implantable drug delivery system according to claim 13, wherein the drug delivery path preservation means comprises a means for delivering a substance for resisting fibrous occlusions through the drug delivery ports.
- 17. An implantable drug delivery system according to claim 13, wherein the drug delivery path preservation means comprises a fluid coating on the catheter.
- 18. An implantable drug delivery system according to claim 13, wherein the drug delivery path preservation means comprises a film on the catheter.
- 19. A method of treating erectile dysfunction comprising the steps of:

implanting a supply of prostaglandin E1 in the body in a device capable of releasing a dose on demand, and

thereafter treating the erectile dysfunction by releasing an effective amount of prostaglandin E1 on demand of the patient.

20. A method of treating erectile dysfunction according to claim 17 further comprising resisting chances of an overdose of the prostaglandin E1 by preventing actuation of the device outside predetermined parameters.